[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457068":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":41,"locations":49,"responsibleParty":123,"collaborators":36,"id":125,"slug":126,"hasResults":127,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":36,"eligibilityCriteria":131,"healthyVolunteers":127,"sex":132,"minAge":133,"maxAge":36,"enrollmentInfo":134,"targetDuration":36,"studyType":137,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":65,"whyStopped":36,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: ALN-APP","EXPERIMENTAL","Participants will be administered a single dose of ALN-APP.",[13],"Drug: ALN-APP",{"label":15,"type":16,"description":17,"interventionNames":18},"Part A: Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo.",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Part B:","Participants will be administered multiple doses of ALN-APP.",[13],[25,32],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","ALN-APP","ALN-APP will be administered intrathecally (IT)",[9,21],[31],"mivelsiran",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Placebo","Placebo will be administered IT",[15],null,[38],{"name":39,"affiliation":5,"role":40},"Medical Director","STUDY_DIRECTOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":36,"email":46},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":43,"role":44,"phone":48,"phoneExt":36,"email":46},"1-877-256-9526",[50,64,74,84,92,102,110,115],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":36},"Clinical Trial Site","COMPLETED","La Jolla","California","92037","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-117.2742,32.84727,{"lat":62,"lon":61},{"facility":51,"status":65,"city":66,"state":67,"zip":68,"country":56,"countryCode":57,"cosmosGeoPoint":69,"geoPoint":73,"contacts":36},"RECRUITING","Indianapolis","Indiana","46202",{"type":59,"coordinates":70},[71,72],-86.15804,39.76838,{"lat":72,"lon":71},{"facility":51,"status":65,"city":75,"state":36,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":83,"contacts":36},"Montreal","H3A 2B4","Canada","CA",{"type":59,"coordinates":80},[81,82],-73.58781,45.50884,{"lat":82,"lon":81},{"facility":51,"status":65,"city":85,"state":36,"zip":86,"country":77,"countryCode":78,"cosmosGeoPoint":87,"geoPoint":91,"contacts":36},"Toronto","M3B 2S7",{"type":59,"coordinates":88},[89,90],-79.39864,43.70643,{"lat":90,"lon":89},{"facility":51,"status":65,"city":93,"state":36,"zip":94,"country":95,"countryCode":96,"cosmosGeoPoint":97,"geoPoint":101,"contacts":36},"Amsterdam","1081 BT","Netherlands","NL",{"type":59,"coordinates":98},[99,100],4.88969,52.37403,{"lat":100,"lon":99},{"facility":51,"status":52,"city":103,"state":36,"zip":104,"country":95,"countryCode":96,"cosmosGeoPoint":105,"geoPoint":109,"contacts":36},"Groningen","9713 GG",{"type":59,"coordinates":106},[107,108],6.56667,53.21917,{"lat":108,"lon":107},{"facility":51,"status":65,"city":111,"state":36,"zip":112,"country":113,"countryCode":114,"cosmosGeoPoint":36,"geoPoint":36,"contacts":36},"Huntley Street","WC1E 6AG","United Kingdom","UK",{"facility":51,"status":65,"city":116,"state":36,"zip":117,"country":113,"countryCode":114,"cosmosGeoPoint":118,"geoPoint":122,"contacts":36},"Sheffield","S10 2JF",{"type":59,"coordinates":119},[120,121],-1.4659,53.38297,{"lat":121,"lon":120},{"type":124,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100457068","phase-1-a-study-to-evaluate-the-safety-and-tolerability-of-aln-app-in-patients-with-eoad-100457068",false,"NCT05231785","A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD","A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer's Disease (EOAD)","Inclusion Criteria:\n\n* Has mild cognitive impairment or mild dementia due to EOAD\n* Has Clinical Dementia Rating (CDR) global score 0.5 or 1.0 and Mini Mental State Examination (MMSE) \\>20\n\nExclusion Criteria:\n\n* Has Non-Alzheimer's disease dementia\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2×upper limit of normal (ULN)\n* Has estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73m\\^2 at Screening\n* Has recently received an investigational agent\n* Has recent treatment with amyloid-targeting antibody\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","ALL","18 Years",{"count":135,"type":136},60,"ESTIMATED","INTERVENTIONAL",[139],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.",[142],"Early-Onset Alzheimer Disease",[144],"EOAD","2026-06-10",{"date":147,"type":148},"2026-06-12","ACTUAL",{"date":150,"type":148},"2022-02-04",{"date":152,"type":136},"2029-04-20",{"name":5,"class":6},8]